{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:37:55Z","timestamp":1772138275025,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41433-019-0652-3","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T13:10:14Z","timestamp":1572268214000},"page":"609-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Anti-VEGF therapy is not a magic bullet for diabetic retinopathy"],"prefix":"10.1038","volume":"34","author":[{"given":"Mingwei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoyao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,28]]},"reference":[{"key":"652_CR1","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2019.5790","volume":"231","author":"CW Baker","year":"2019","unstructured":"Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, et al. DRCR retina network. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;231:1880\u201394.","journal-title":"JAMA."},{"key":"652_CR2","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","volume":"314","author":"Writing Committee for the Diabetic Retinopathy Clinical Research Network.","year":"2015","unstructured":"Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy:a randomized clinical trial. JAMA. 2015;314:2137\u201346.","journal-title":"JAMA."},{"key":"652_CR3","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","volume":"389","author":"S Sivaprasad","year":"2017","unstructured":"Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389:2193\u2013203.","journal-title":"Lancet."},{"key":"652_CR4","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","volume":"136","author":"JG Gross","year":"2018","unstructured":"Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, et al. Diabetic retinopathy clinical research network. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Opthalmol. 2018;136:1138\u201348.","journal-title":"JAMA Opthalmol"},{"key":"652_CR5","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351\u20139.","journal-title":"Ophthalmology."},{"key":"652_CR6","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.oret.2018.06.005","volume":"2","author":"CC Wykoff","year":"2018","unstructured":"Wykoff CC, Eichenbaum DA, Roth DB, Hill L, Fung AE, Haskova Z. Ranibizumab induces regression of diabetic retinopathy in most patients at high risk of progression to proliferative diabetic retinopathy. Ophthalmol Retin. 2018;2:997\u20131009.","journal-title":"Ophthalmol Retin"},{"key":"652_CR7","first-page":"851","volume":"50","author":"Guidelines for clinical diagnosis and treatment of diabetic retinopathy.","year":"2014","unstructured":"Guidelines for clinical diagnosis and treatment of diabetic retinopathy. Fundus workshop of Chinese Ophthalmological Society. Chin J Ophthalmol. 2014;50:851\u201365.","journal-title":"Chin J Ophthalmol."},{"key":"652_CR8","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1167\/iovs.17-23509","volume":"59","author":"L Nicholson","year":"2018","unstructured":"Nicholson L, Crosby-Nwaobi R, Vasconcelos JC, Prevost AT, Ramu J, Riddell A, et al. Mechanistic evaluation of panretinal photocoagulation versus aflibercept in proliferative diabetic retinopathy: CLARITY substudy. Investig Ophthalmol Vis Sci. 2018;59:4277\u201384.","journal-title":"Investig Ophthalmol Vis Sci."},{"key":"652_CR9","first-page":"565","volume":"55","author":"M Zhao","year":"2019","unstructured":"Zhao M, Sun Y, Xu X. The rational use of anti-vegf drugs to assist the treatment of diabetic retinopathy. Chin J Ophthalmol. 2019;55:565\u20138.","journal-title":"Chin J Ophthalmol."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41433-019-0652-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-019-0652-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-019-0652-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:08:53Z","timestamp":1684616933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-019-0652-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,28]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1038\/s41433-019-0652-3","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,28]]},"assertion":[{"value":"13 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}